ClinicalTrials.gg
WithdrawnNCT04671355Updated Feb 3, 2022

TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

A Phase 4 interventional study of Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg and Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg in COPD, sponsored by Chiesi Farmaceutici S.p.A.. Withdrawn. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-02-03.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Continuing delays due to COVID-19 pandemic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..

Enrollment
59th of 59
0 · median 65
Started
2021
with 6 others
Phase 4
3 of 68
none open now
Registered
50th of 68
by date

Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 59th largest by enrollment of the 59 interventional ones that give a count, is one of 7 that started in 2021, is one of 3 in phase 4, and was the 50th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

Efficacy of TRIMBOW® pMDI and RELVAR® ELLIPTA® DPI on lung stiffness reduction assessed through area under the reactance curve (AX) using oscillometry in chronic obstructive pulmonary disease (COPD).

Read the detailed description

An open label, multicentre, randomised, 2-way cross-over exploratory clinical trial comparing a fixed combination of beclometasone dipropionate plus formoterol fumarate plus glycopyrronium administered via pMDI (TRIMBOW®) and a fixed combination of fluticasone furoate plus vilanterol administered via DPI (RELVAR® ELLIPTA®) on lung stiffness reduction assessed through area under the reactance curve (AX) using forced oscillation technique (FOT) in patients with chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • COPD

Keywords

  • Small Airways Disorders and Forced Oscillation Technique
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient's written obtained prior to any study related procedures.
  2. Male or female patients aged 40 years and above.
  3. Patients with established diagnosis of at least 12 months prior to the screening visit (according to GOLD Report, revised 2019). Patients with a diagnosis of Asthma COPD Overlap Syndrome (ACOS) and with a current diagnosis of atopy or allergic rhinitis based on their medical history and investigator judgement will be also eligible for inclusion.
  4. Current smokers or ex-smokers, who quit smoking at least 6 months prior to screening visit, with a smoking history of at least 10 pack years [pack-years = (number of cigarettes per day x number of years)/20]. If patients underwent any kind of smoking cessation therapy, it should be finished at least 2 months prior to screening.
  5. A post-bronchodilator \<60 % of the predicted normal value and a post-bronchodilator FEV1/FVC \< 0.7 within 30 min after 4 puffs (4 x 100 µg) of salbutamol pMDI.

    If this criterion is not met at screening, the test can be repeated once before randomisation.

  6. Patients under double or triple therapy for at least 2 months prior to screening visit in stable doses and regimens with either:

    1. inhaled /long-acting β2-agonist combination (ICS/LABA) (fixed or free), or
    2. inhaled corticosteroids/long-acting muscarinic antagonist free combination (ICS/LAMA), or
    3. Inhaled long-acting β2-agonist / long-acting muscarinic antagonist (LABA/LAMA) (fixed or free), or
    4. fixed or free combination of an inhaled corticosteroid /long-acting β2-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)
  7. A cooperative attitude and ability to correctly use the study inhalers and spacer.
  8. Female patients must be either of non- (WONCBP) defined as physiologically incapable of becoming pregnant (i.e. or permanently sterile) or physiologically capable of becoming pregnant (i.e. women of childbearing potential (WOCBP) fulfilling one of the following criteria:

    1. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective method from the signature of the informed consent and until the follow-up contact or
    2. WOCBP with non-fertile male partners (contraception is not required in this case).For the definition of WONCBP, WOCBP, fertile men, and the list of highly effective birth control methods, refer to Appendix 3 (or section 4.1 of the CTFG guidance).

Any postmenopausal women (physiologic menopause defined as "12 consecutive months of amenorrhea") or women permanently sterilized (e.g. bilateral oophorectomy, hysterectomy or bilateral salpingectomy) may be enrolled in the Study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of ) UNLESS are willing to use one or more of the highly effective method as reported in Appendix 3 (or section 4.1 of the CTFG guidance).
  2. Diagnosis of asthma.
  3. Patients requiring use of the following medications:

    i. A course of systemic longer than 3 days for exacerbation in the 4 weeks prior to screening.

    ii. A longer than 7-day course of antibiotics for the treatment of COPD exacerbation in the 4 weeks prior to screening.

    iii. Use of antibiotics for a lower respiratory tract infection (e.g pneumonia) in the 4 weeks prior to screening.

  4. COPD exacerbation requiring prescriptions of systemic corticosteroids and/or antibiotics or hospitalization during the run-in period.
  5. Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.
  6. Known respiratory disorders other than COPD which may impact the efficacy of the study drug according the investigator's judgment. This can include but is not limited to alfa-1 antitrypsin deficiency, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension and interstitial lung disease.
  7. Patients who have clinically severe cardiovascular condition (such as but not limited to unstable ischemic heart disease, Class III/IV, left ventricular failure, acute myocardial infarction, not controlled arrhythmia etc.), which may impact the efficacy or the safety of the study drug according to the investigator's judgement
  8. An abnormal and 12-lead which may impact the safety of the patient according to investigator's judgement. Patients whose electrocardiogram (ECG) (12 lead) shows >450 ms for males or QTcF >470 ms for females at screening or at randomisation visits are not eligible. The QTcF criterion should not be applicable to patients with pacemaker or permanent atrial fibrillation.
  9. Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic agents.
  10. History of to anticholinergics, β2-agonist, corticosteroids or any of the contained in any of the formulations used in the trial which may raise or impact the efficacy of the study drug according to the investigator's judgement.
  11. Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study drug according to investigator's judgement.
  12. Unstable concurrent disease: e.g. fever, uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; uncontrolled gastrointestinal disease (e.g. active peptic ulcer); uncontrolled neurological disease; uncontrolled haematological disease; uncontrolled disorders, or other which may impact the efficacy or the safety of the study drug according to investigator's judgment.
  13. History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening visit.
  14. Participation in another clinical trial where drug was received less than 30 days or 5 half-lives whichever is longer prior to screening visit
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Trimbow

    Pressurized metered dose inhaler

    Drug: Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg

  • Active comparator
    Relvar

    Dry powder inhaler

    Drug: Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg

Interventions

  • DrugBeclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg

    Pressurized metered dose inhaler

  • DrugFluticasone Furoate / Vilanterol Trifenatate 100/25 mcg

    Dry powder inhaler

06

What researchers measure

Primary outcomes

  1. Oscillometry - Reactance (AX)

    Area under the curve of Reactance (AX) 5-120 minutes post-dose

    Time frame: 4 weeks

Secondary outcomes

  1. Oscillometry - Resistance at 5 Hertz (R5)

    Change from baseline 5-120 minutes post-dose

    Time frame: 4 weeks

  2. Spirometry - Forced Expiratory Volume in the first second

    Change from baseline in pre-dose and post-dose (30, 60 and 120 minutes post-dose)

    Time frame: 4 weeks

  3. Health status

    Change from baseline in COPD Assessment Test (CAT) score

    Time frame: 4 weeks

  4. Safety monitoring - incidence of adverse events (AEs) and adverse drug reactions (ADRs)

    Recording of AEs and ADRs

    Time frame: Overall study period and by Treatments (4 weeks)

  5. Oscillometry - Resistance at 19 Hertz (R19) and 20 Hertz (R20)

    Change from baseline 5-120 minutes post-dose

    Time frame: 4 weeks

  6. Oscillometry - Resonance frequency (RF)

    Change from baseline 5-120 minutes post-dose

    Time frame: 4 weeks

  7. Spirometry - Forced Vital Capacity

    Change from baseline in pre-dose and post-dose (30, 60 and 120 minutes post-dose)

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Data sharing details ↗ · www.chiesi.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2021; primary completion for Dec 2021, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2020
First posted
Dec 17, 2020
StartEst.
Oct 4, 2021
Primary completionEst.
Dec 22, 2021
CompletionEst.
Feb 18, 2022
Last update
Feb 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04671355
Responsible party
Sponsor
First posted
Dec 17, 2020
Start date
Oct 4, 2021 (estimated)
Primary completion
Dec 22, 2021 (estimated)
Completion
Feb 18, 2022 (estimated)
Last update
Feb 3, 2022

Study contacts

Brian Lipworth, MD
study director · Ninewells Hospital, University of Dundee, Scotland, UK
Catherine Jackson, MD
principal investigator · University of Central Lancashire, Burnley, UK

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion